Results 1 to 10 of about 58,915 (315)

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Nature Medicine, 2022
Previous studies have suggested that the gut microbiome influences the response to checkpoint inhibitors (CPIs) in patients with cancer. CBM588 is a bifidogenic live bacterial product that we postulated could augment CPI response through modulation of ...
Nazli Dizman, Luis Meza, Tanya B Dorff
exaly   +2 more sources

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

Nature, 2022
Standard first-line chemotherapy results in disease progression and death within one year in most patients with human epidermal growth factor receptor 2 (HER2)-negative gastro-oesophageal adenocarcinoma1–4.
Kohei Shitara, Jaffer A Ajani, Lucjan S Wyrwicz   +2 more
exaly   +2 more sources

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial

Journal for ImmunoTherapy of Cancer, 2023
Talimogene laherparepvec (T-VEC) plus ipilimumab has demonstrated greater antitumor activity versus ipilimumab alone, without additional toxicity, in patients with advanced melanoma.
Celeste Lebbe, Parminder Singh, Omid Hamid, Frances A Collichio, Igor Puzanov, Merrick Ross, Theodore Logan, Philip Friedlander, Claus Garbe, Janice M Mehnert, John Glaspy, Axel Hauschild, Wendy Snyder, Jason A Chesney, Mohammed M Milhem, Harshada Joshi   +15 more
doaj   +2 more sources

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

Nature Medicine, 2023
The combination of neoadjuvant nivolumab, ipilimumab and chemotherapy showed promising efficacy in patients with resectable non-small cell lung cancer, with higher tumor immune cell infiltration and tertiary lymphoid structures after treatment compared ...
Tina Cascone, Sreyashi Basu, Ansam Sinjab   +2 more
exaly   +2 more sources

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Nature Medicine, 2021
Tina Cascone, William N William, Annikka Weissferdt   +2 more
exaly   +2 more sources

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Nature Medicine, 2022
Robyn P M Saw, Ellen H W Kapiteijn, Astrid A M Van Der Veldt   +2 more
exaly   +2 more sources

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Lancet, The, 2021
Arnaud Scherpereel, Anna K Nowak, Nobukazu Fujimoto   +2 more
exaly   +2 more sources

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

New England Journal of Medicine, 2010
F Stephen Hodi, David F Mcdermott, Caroline Robert   +2 more
exaly   +2 more sources

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

Nature Medicine, 2023
Ari VanderWalde, Katie M Campbell, Philip O Scumpia   +2 more
exaly   +2 more sources

Adjuvant Treatments of Adult Melanoma: A Systematic Review and Network Meta-Analysis

Frontiers in Oncology, 2022
Multiple treatments of unresectable advanced or metastatic melanoma have been licensed in the adjuvant setting, causing tremendous interest in developing neoadjuvant strategies for melanoma.
Mingyi Jing, Mingyi Jing, Yi Cai, Jing Shi, Xufan Zhang, Baohua Zhu, Baohua Zhu, Fan Yuan, Fan Yuan, Jie Zhang, Jie Zhang, Min Xiao, Mingling Chen   +12 more
doaj   +1 more source